Novo Nordisk's Imminent Capacity Increase is a Significant Positive -- Market Talk

Dow Jones

Dec 16, 2024

0838 GMT - Regulatory clearance of Novo Holdings' planned acquisition of Catalent is a significant positive for Novo Nordisk, Intron Health analyst Naresh Chouhan writes. Novo Holdings will buy U.S. contract drug maker Catalent before selling three of Catalent's production sites to Novo Nordisk. The deal has not been challenged by the Federal Trade Commission, paving the way for the deal to close in the coming days. "This is a very significant positive in our view and has both long-term and short-term upside ramifications." Intron Health believes the extra capacity will allow Novo Nordisk to boost Wegovy production and give it considerable manufacturing might which could also help deter competitors from investing in biosimilars. Shares rise 2.1% to 769.70 Danish kroner. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

December 16, 2024 03:38 ET (08:38 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2491516026"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2491516026\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2491516026?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-16 16:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2491516026","market":"sh","top_or_hot":-1,"title":"Novo Nordisk's Imminent Capacity Increase is a Significant Positive -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0838 GMT - Regulatory clearance of Novo Holdings' planned acquisition of <a href=\"https://laohu8.com/S/CTLT\">Catalent</a> is a significant positive for Novo Nordisk, Intron Health analyst Naresh Chouhan writes. Novo Holdings will buy U.S. contract drug maker Catalent before selling three of Catalent's production sites to Novo Nordisk. The deal has not been challenged by the Federal Trade Commission, paving the way for the deal to close in the coming days. \"This is a very significant positive in our view and has both long-term and short-term upside ramifications.\" Intron Health believes the extra capacity will allow Novo Nordisk to boost Wegovy production and give it considerable manufacturing might which could also help deter competitors from investing in biosimilars. Shares rise 2.1% to 769.70 Danish kroner. (dominic.chopping@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 16, 2024 03:38 ET (08:38 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk's Imminent Capacity Increase is a Significant Positive -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk's Imminent Capacity Increase is a Significant Positive -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-12-16 16:38</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0838 GMT - Regulatory clearance of Novo Holdings' planned acquisition of <a href=\"https://laohu8.com/S/CTLT\">Catalent</a> is a significant positive for Novo Nordisk, Intron Health analyst Naresh Chouhan writes. Novo Holdings will buy U.S. contract drug maker Catalent before selling three of Catalent's production sites to Novo Nordisk. The deal has not been challenged by the Federal Trade Commission, paving the way for the deal to close in the coming days. \"This is a very significant positive in our view and has both long-term and short-term upside ramifications.\" Intron Health believes the extra capacity will allow Novo Nordisk to boost Wegovy production and give it considerable manufacturing might which could also help deter competitors from investing in biosimilars. Shares rise 2.1% to 769.70 Danish kroner. (dominic.chopping@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 16, 2024 03:38 ET (08:38 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CTLT","symbol_name":"Catalent","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2491516026","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2491516026","pubTimestamp":1734338280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0838 GMT - Regulatory clearance of Novo Holdings' planned acquisition of Catalent is a significant positive for Novo Nordisk, Intron Health analyst Naresh Chouhan writes. Novo Holdings will buy U.S. contract drug maker Catalent before selling three of Catalent's production sites to Novo Nordisk. The deal has not been challenged by the Federal Trade Commission, paving the way for the deal to close in the coming days. \"This is a very significant positive in our view and has both long-term and short-term upside ramifications.\" Intron Health believes the extra capacity will allow Novo Nordisk to boost Wegovy production and give it considerable manufacturing might which could also help deter competitors from investing in biosimilars. Shares rise 2.1% to 769.70 Danish kroner. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CTLT":"Catalent","BK4588":"碎股","BK4585":"ETF&股票定投概念","NVO":"诺和诺德","BK4530":"医药外包概念","BK4007":"制药"},"translate_title":"诺和诺德即将增加产能是一个重大利好——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTLT":0.9,"NVO":1},"content_text":"0838 GMT - Regulatory clearance of Novo Holdings' planned acquisition of Catalent is a significant positive for Novo Nordisk, Intron Health analyst Naresh Chouhan writes. Novo Holdings will buy U.S. contract drug maker Catalent before selling three of Catalent's production sites to Novo Nordisk. The deal has not been challenged by the Federal Trade Commission, paving the way for the deal to close in the coming days. \"This is a very significant positive in our view and has both long-term and short-term upside ramifications.\" Intron Health believes the extra capacity will allow Novo Nordisk to boost Wegovy production and give it considerable manufacturing might which could also help deter competitors from investing in biosimilars. Shares rise 2.1% to 769.70 Danish kroner. (dominic.chopping@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 16, 2024 03:38 ET (08:38 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}